Canine AGP antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Canine AGP antibodies pairs and antigen for animal health (animal Dog/Canine Systemic Inflammation) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Companion Animal disease testing products collection >>

Product information

Size： 1mg | 10mg | 100mg

Product Description

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker Information

Alpha-1 Acid Glycoprotein (AGP), in the context of canine health, serves as a pivotal biomarker for identifying and monitoring inflammation, infection, and disease states in dogs. This acute phase protein, also known in veterinary circles as Dog/Canine AGP, rises in response to systemic stressors such as infection, inflammation, and trauma, offering veterinarians a sensitive and specific tool for assessing the health status of their canine patients.

AGP's role in canine medicine is multifaceted. Primarily, it acts as an early warning system, alerting veterinarians to underlying health issues before clinical symptoms become evident. This is particularly valuable for diseases that progress silently or are in their nascent stages, such as certain cancers, autoimmune diseases, or chronic infections. By enabling early detection, AGP measurements can facilitate prompt intervention, potentially improving the outcome for the affected dog.

Beyond its utility in detection, Dog/Canine AGP is instrumental in monitoring disease progression and treatment efficacy. For chronic conditions or diseases requiring long-term management, AGP levels can reflect changes in the disease state, helping veterinarians tailor treatment plans to the individual needs of their patients. A decrease in AGP levels often signifies a positive response to treatment, while an increase may indicate a worsening condition or the emergence of complications.

Moreover, AGP serves as a prognostic indicator in canine health. Elevated AGP levels at diagnosis or during treatment can be associated with more severe disease presentations and may have prognostic implications. This information aids veterinarians in making informed decisions about treatment options and managing pet owner expectations regarding their dog's health outcomes.

The assessment of AGP levels in dogs is achieved through specific diagnostic tests that measure this protein's concentration in the blood. The development and refinement of these tests underscore the growing recognition of the importance of species-specific biomarkers in veterinary medicine. As research continues to evolve, the potential for AGP and other biomarkers to refine our understanding of canine diseases and improve clinical outcomes for dogs is significant.

In summary, Dog/Canine AGP is an essential biomarker for detecting, monitoring, and prognosticating health issues in dogs. Its ability to signal the presence of systemic inflammation and disease before the onset of overt clinical symptoms empowers veterinarians to act proactively in managing canine health. Furthermore, its role in evaluating treatment effectiveness and disease progression enhances the precision of canine medical care. As veterinary science advances, the role of AGP and similar biomarkers in improving the diagnosis, treatment, and management of canine diseases is likely to expand, offering new avenues for enhancing the health and well-being of dogs.

About GDU